The Potential of Nano-Vehicle Mediated Therapy in Vasculitis and Multiple Sclerosis

Author(s): R. Huis In ’t Veld, C.G. Da Silva, E.L. Kaijzel, A.B. Chan, L.J. Cruz*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 13 , 2017

Become EABM
Become Reviewer
Call for Editor


The induction of immune tolerance towards self-antigens presents as a viable future strategy in the treatment of auto-immune diseases, including vasculitis and multiple sclerosis (MS). As specific targets are currently lacking for vasculitis due to incomplete understanding of the pathologies underlying this disease, current treatment options are based on modalities that induce general immune suppression. However, many immune suppressants used in the clinic are known to display wide biodistribution and are thus often accompanied by several adverse effects. Nano-vehicles (NVs) possess the ability to overcome such limitations by enabling more specific delivery of their content through modifications with targeting moieties. In this review, we describe the latest insights in the pathology of vasculitis that may function as potential targets for NV carrier systems, allowing more specific delivery of currently used immune suppressants. In addition, we describe the existing strategies to induce artificial immune tolerance and explore the feasibility of inducing regulatory T cell (Treg) mediated tolerance for MS, possibly mediated by NVs.

Keywords: Nano-vehicle, nanoparticle, vasculitis, multiple sclerosis, drug delivery, targeting, drug release, immune suppressive drugs, nanomedicine, glucocorticosteroids.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 23 May, 2017
Page: [1985 - 1992]
Pages: 8
DOI: 10.2174/1381612822666161221151900
Price: $65

Article Metrics

PDF: 25